Compugen to Release Fourth Quarter and Full Year 2021 Results on Thursday, February 24, 2022
Compugen Ltd. (CGEN) will announce its fourth quarter and full year 2021 financial results on February 24, 2022, before U.S. market open. Management will conduct a conference call and webcast at 8:30 AM ET to discuss the results and provide corporate updates. Compugen is focused on cancer immunotherapy, with lead candidate COM701 in Phase 1 studies. The company also has partnered programs with Bayer and AstraZeneca. Interested parties may access the call via phone or webcast, with a replay available post-event.
- Upcoming financial results may provide insights into company performance.
- Lead product COM701 is in Phase 1 studies, indicating progress in drug development.
- None.
HOLON, Israel, Feb. 10, 2022 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, announced today that the Company will release its fourth quarter and full year 2021 financial results on Thursday, February 24, 2022, before the U.S. financial markets open. Management will host a conference call and webcast to review the results and provide a corporate update at 8:30 AM ET.
To access the live conference call by telephone, please dial 1-866-744-5399 from the U.S., or +972-3-918-0644 internationally. The call will be available via live webcast through Compugen's website, located at the following link.
Following the live webcast, a replay will be available on the Company's website.
About Compugen
Compugen is a clinical-stage discovery and development company utilizing its broadly applicable, predictive computational discovery platforms to identify novel drug targets and develop therapeutics in the field of cancer immunotherapy. Compugen's lead product candidate, COM701, a potential first-in-class anti-PVRIG antibody, for the treatment of solid tumors, is undergoing Phase 1 studies in dual, and triple combinations. COM902, Compugen's second fully owned clinical antibody targeting TIGIT, for the treatment of solid and hematological tumors, is undergoing Phase 1 studies as a single agent and in dual combination. Partnered programs include bapotulimab, a therapeutic antibody in Phase 1 development targeting ILDR2 licensed to Bayer under a research and discovery collaboration and license agreement, and AZD2936, a TIGIT/PD-1 bispecific in Phase 1 development derived from COM902 through a license agreement with AstraZeneca for the development of bispecific and multi-specific antibodies. Compugen's therapeutic pipeline of early-stage immuno-oncology programs includes myeloid targets. Compugen is headquartered in Israel, with offices in South San Francisco, CA. Compugen's shares are listed on Nasdaq and the Tel Aviv Stock Exchange under the ticker symbol CGEN. For additional information, please visit Compugen's corporate website at www.cgen.com.
Investor Relations contact:
Yvonne Naughton, PhD
Head of Investor Relations and Corporate Communications Compugen Ltd.
Email: ir@cgen.com
Tel: +1 (628) 241-0071
View original content:https://www.prnewswire.com/news-releases/compugen-to-release-fourth-quarter-and-full-year-2021-results-on-thursday-february-24-2022-301479585.html
SOURCE Compugen Ltd.
FAQ
When will Compugen (CGEN) release its financial results?
What time is the Compugen (CGEN) conference call?
How can I access the Compugen (CGEN) conference call?
What is the status of Compugen's lead product COM701?
Which companies are partners of Compugen (CGEN)?
